ZyVersa Therapeutics, Inc. announced new findings highlighting the role of microglial-driven inflammation in the progression of Parkinson's Disease (PD), as detailed in their recent study published in ...

ZyVersa Therapeutics, a biopharmaceutical company focused on developing treatments for renal and inflammatory diseases, announced the issuance of a Shareholder Letter from CEO Stephen C. Glover. The ...

The paper, published in Pharmaceuticals, demonstrates that pyrin inflammasome-mediated inflammation induced by traumatic brain injury (TBI) contributes to cardiovascular co-morbidities through ...

Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study. Parkinson ...

Data demonstrate that extracellular ASC specks, independent of IL-1β, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which is characterized by deposition of insoluble amyloid ...

Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP. This study demonstrated that CKD-induced IL-1β ...

WESTON, Fla., Sept. 8, 2020 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and ...

Implantation of biomaterials and devices into soft tissues leads to the development of the foreign body response (FBR), which can interfere with implant function and eventually lead to failure. The ...